These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26017814)

  • 1. Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.
    Kim E; Yang KS; Kohler RH; Dubach JM; Mikula H; Weissleder R
    Bioconjug Chem; 2015 Aug; 26(8):1513-8. PubMed ID: 26017814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
    Kawahata W; Asami T; Fujii I; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Whang JA; Chang BY
    Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.
    Douhan J; Miyashiro JS; Zhou X; Cole DC; Wu PW; Collins M; Dunussi-Joannopoulos K
    Assay Drug Dev Technol; 2007 Dec; 5(6):751-8. PubMed ID: 18181691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
    Asami T; Kawahata W; Sawa M
    Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
    Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
    J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
    Uckun FM; Qazi S
    Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
    Rankin AL; Seth N; Keegan S; Andreyeva T; Cook TA; Edmonds J; Mathialagan N; Benson MJ; Syed J; Zhan Y; Benoit SE; Miyashiro JS; Wood N; Mohan S; Peeva E; Ramaiah SK; Messing D; Homer BL; Dunussi-Joannopoulos K; Nickerson-Nutter CL; Schnute ME; Douhan J
    J Immunol; 2013 Nov; 191(9):4540-50. PubMed ID: 24068666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of BTK inhibitors for the treatment of B-cell malignancies.
    Kim HO
    Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
    Uckun F; Ozer Z; Vassilev A
    Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
    MacPartlin M; Smith AM; Druker BJ; Honigberg LA; Deininger MW
    Leukemia; 2008 Jul; 22(7):1354-60. PubMed ID: 18548107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes.
    Brunner C; Avots A; Kreth HW; Serfling E; Schuster V
    Immunobiology; 2002 Oct; 206(4):432-40. PubMed ID: 12437073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
    de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
    Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.
    Byrne JC; Ní Gabhann J; Stacey KB; Coffey BM; McCarthy E; Thomas W; Jefferies CA
    J Immunol; 2013 May; 190(10):5207-15. PubMed ID: 23596312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
    Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
    J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.